Early trial tests new drug combo for Tough-to-Treat blood cancer
NCT ID NCT03091257
Summary
This is an early-stage study testing whether two targeted cancer drugs, dabrafenib and trametinib, can help control multiple myeloma that has come back or stopped responding to other treatments. The study will enroll about 30 adults whose cancer has a specific genetic change (in the BRAF, KRAS, or NRAS genes). The goal is to see if these drugs, given alone or together, are safe and can effectively kill the cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.